Pubblicazioni

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO

2021 - BRITISH JOURNAL OF CANCER

Rossini, D.; Lonardi, S.; Antoniotti, C.; Santini, D.; Tomasello, G.; Ermacora, P.; Germani, M. M.; Bergamo, F.; Ricci, V.; Caponnetto, S.; Moretto, R.; Zaniboni, A.; Pietrantonio, F.; Buonadonna, A.; Ritorto, G.; Masi, G.; Latiano, T. P.; Rapisardi, S.; Falcone, A.; Cremolini, C.

Resection or stenting in the treatment of symptomatic advanced metastatic rectal cancer. A dilemma

2019 - ANTICANCER RESEARCH

Fiori, E.; Crocetti, D.; Lamazza, A.; De Felice, F.; Tarallo, M.; Sterpetti, A. V.; Mingoli, A.; Sapienza, P.; De Toma, G.

Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases

2018 - EUROPEAN JOURNAL OF SURGICAL ONCOLOGY

Berardi, Giammauro; De Man, Marc; Laurent, StÃ©phanie; Smeets, Peter; Tomassini, Federico; Ariotti, Riccardo; Hoorens, Anne; van Dorpe, Jo; Varin, Oswald; Geboes, Karen; Troisi, Roberto I

Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial

2016 - ANNALS OF ONCOLOGY

Lonardi, S.; Sobrero, A.; Rosati, G.; Di Bartolomeo, M.; Ronzoni, M.; Aprile, G.; Scartozzi, M.; Banzi, M.; Zampino, M. G.; Pasini, F.; Marchetti, P.; Cantore, M.; Zaniboni, A.; Rimassa, L.; Ciuffreda, L.; Ferrari, D.; Barni, S.; Zagonel, V.; Maiello, E.; Rulli, E.; Labianca, Roberto